FDA Clears SIMLANDI Process 2.0, More Than Doubling Output Per Batch
ALVO sits 84% above its 52-week low of $2.94.
Summary
The FDA approved a new manufacturing process for SIMLANDI, Alvotech's Humira biosimilar, allowing drug substance production in the Reykjavik DSM2 suite to more than double output per batch without changing the upstream manufacturing scale. The company says comparability to the prior process was demonstrated, so product quality, safety and efficacy are unchanged. The practical effect is fewer batches for the same volume, freeing capacity for the rest of the biosimilar portfolio and giving more supply flexibility as demand grows. This comes after the July FDA close-out of the Reykjavik facility inspection and the October 5 approval of a second drug substance production suite, so it extends a run of manufacturing-capacity wins rather than opening a new regulatory front. Modest but real: it supports the FY26 revenue guidance of $650M-$700M by easing supply constraints, though no financial terms or capacity figures were disclosed.
At the time of this announcement, ALVO was trading at $5.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.94 to $8.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.